Molecules 2009, 14(6), 2256-2272; doi:10.3390/molecules14062256
Article

Heterocyclic-2-carboxylic Acid (3-Cyano-1,4-di-N-oxidequinoxalin-2-yl)amide Derivatives as Hits for the Development of Neglected Disease Drugs

Saioa Ancizu 1 email, Elsa Moreno 1 email, Enrique Torres 1 , Asunción Burguete 1 , Silvia Pérez-Silanes 1 , Diego Benítez 2 email, Raquel Villar 1 , Beatriz Solano 1 , Adoración Marín 1 , Ignacio Aldana 1 , Hugo Cerecetto 2 email, Mercedes González 2,* email and Antonio Monge 1,* email
1 Unidad en Investigación y Desarrollo de Medicamentos, Centro de Investigación en Farmacobiología Aplicada (CIFA), University of Navarra, C/Irunlarrea s/n, 31008 Pamplona, Spain 2 Laboratorio de Química Orgánica, Facultad de Ciencias/Facultad de Química, Universidad de la República, Iguá 4225, 11400 Montevideo, Uruguay
* Authors to whom correspondence should be addressed.
Received: 2 June 2009; in revised form: 15 June 2009 / Accepted: 17 June 2009 / Published: 22 June 2009
(This article belongs to the Special Issue Neglected Diseases: Medicinal Chemistry and Natural Product Chemistry)
PDF Full-text Download PDF Full-Text [149 KB, uploaded 22 June 2009 03:22 CEST]
Abstract: Neglected diseases represent a major health problem. It is estimated that one third of the world population is infected with tuberculosis (TB). Besides TB, Chagas disease, affects approximately 20 million people. Quinoxalines display great activities against TB and Chagas. Forty new quinoxaline 1,4-di-N-oxide derivatives have been prepared and tested against M. tuberculosis and T. cruzi. Carboxylic acid quinoxaline 1,4-di-N-oxides (CAQDOs) 5 and 17 showed MIC values on the same order as the reference antituberculosis drug, rifampicin. Meanwhile, CAQDOs 12 and 22 presented IC50 values in the same order as the anti-chagasic drug, nifurtimox.
Keywords: quinoxaline; neglected diseases; Mycobacterium tuberculosis; Trypanosoma cruzi

Article Statistics

Click here to load and display the download statistics.

Cite This Article

MDPI and ACS Style

Ancizu, S.; Moreno, E.; Torres, E.; Burguete, A.; Pérez-Silanes, S.; Benítez, D.; Villar, R.; Solano, B.; Marín, A.; Aldana, I.; Cerecetto, H.; González, M.; Monge, A. Heterocyclic-2-carboxylic Acid (3-Cyano-1,4-di-N-oxidequinoxalin-2-yl)amide Derivatives as Hits for the Development of Neglected Disease Drugs. Molecules 2009, 14, 2256-2272.

AMA Style

Ancizu S, Moreno E, Torres E, Burguete A, Pérez-Silanes S, Benítez D, Villar R, Solano B, Marín A, Aldana I, Cerecetto H, González M, Monge A. Heterocyclic-2-carboxylic Acid (3-Cyano-1,4-di-N-oxidequinoxalin-2-yl)amide Derivatives as Hits for the Development of Neglected Disease Drugs. Molecules. 2009; 14(6):2256-2272.

Chicago/Turabian Style

Ancizu, Saioa; Moreno, Elsa; Torres, Enrique; Burguete, Asunción; Pérez-Silanes, Silvia; Benítez, Diego; Villar, Raquel; Solano, Beatriz; Marín, Adoración; Aldana, Ignacio; Cerecetto, Hugo; González, Mercedes; Monge, Antonio. 2009. "Heterocyclic-2-carboxylic Acid (3-Cyano-1,4-di-N-oxidequinoxalin-2-yl)amide Derivatives as Hits for the Development of Neglected Disease Drugs." Molecules 14, no. 6: 2256-2272.

Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert